Analyse rétrospective de 24 glioblastomes récidivant après radiochimiothérapie concomitante et traités par nitrosourées ou par l'association irinotécan et bévacizumab. [Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab]
| Autor: | Vauleon, Elodie, Mesbah, Habiba, Gedouin, Daniel, Lecouillard, Isabelle, Louvel, Guillaume, Hamlat, Abderrahmane, Riffaud, Laurent, Carsin, Béatrice, Quillien, Véronique, Audrain, Odile, Lesimple, Thierry |
|---|---|
| Přispěvatelé: | Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS), Département d'oncologie médicale [Rennes], CRLCC Eugène Marquis (CRLCC), Département d'informatique médicale, Service de radiothérapie, Service de neurochirurgie [Rennes] = Neurosurgery [Rennes], CHU Pontchaillou [Rennes], Service de radiologie et imagerie médicale [Rennes] = Radiology [Rennes], Service de Biologie, De Villemeur, Hervé, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS) |
| Jazyk: | francouzština |
| Rok vydání: | 2012 |
| Předmět: |
MESH: Radiation-Sensitizing Agents
recurrence MESH: Carmustine [SDV.CAN]Life Sciences [q-bio]/Cancer bevacizumab MESH: Lomustine MESH: Dacarbazine [SDV.CAN] Life Sciences [q-bio]/Cancer MESH: Nitrosourea Compounds neoplasms MESH: Cohort Studies irinotecan MESH: Angiogenesis Inhibitors MESH: Chemoradiotherapy MESH: Aged MESH: Humans MESH: Middle Aged MESH: Glioblastoma glioblastoma MESH: Adult MESH: Retrospective Studies eye diseases MESH: Drug Therapy Combination MESH: Antineoplastic Combined Chemotherapy Protocols MESH: Antibodies Monoclonal Humanized MESH: Chemotherapy Adjuvant MESH: Brain Neoplasms MESH: Camptothecin sense organs MESH: Neoplasm Recurrence Local |
| Zdroj: | Bulletin du Cancer Bulletin du Cancer, 2012, 99 (2), pp.121-6. ⟨10.1684/bdc.2011.1528⟩ Bulletin du Cancer, John Libbey Eurotext, 2012, 99 (2), pp.121-6. ⟨10.1684/bdc.2011.1528⟩ |
| ISSN: | 0007-4551 1769-6917 |
| DOI: | 10.1684/bdc.2011.1528⟩ |
| Popis: | International audience; Despite progress in the initial management of glioblastoma (GB), the vast majority of patients will experience recurrence within 2-3 years. The medical treatment of these recurrences is being modified by the use of antiangiogenic therapies. Twenty-four patients, who relapsed from GB after chemoradiation followed by adjuvant temozolomide in Rennes, were treated by conventional chemotherapy (nitrosourea) or by the combination of irinotecan and bevacizumab. In this retrospective analysis, overall survival from diagnosis of recurrence was significantly longer in patients treated with the combination of bevacizumab and irinotecan than with nitrosourea (5 months versus 11.5 months). The combination of irinotecan and bevacizumab appeared to provide clinical benefit to patients with recurrent GB. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|